As CEO of HealthAI – The Global Agency for Responsible AI in Health, how do you see artificial intelligence (AI) driven data analytics improving cost transparency and care coordination between private hospitals and international medical insurers?

AI can create transparency by analysing and standardising how healthcare costs are measured and compared across different systems and currencies. Given that 20–40% of our health expenditure today is being wasted on things that do not contribute to improving outcomes, representing US$3 trillion globally, predictive analytics can identify cost variations in real time, allowing medical insurers to route patients to the most appropriate facilities based on clinical need and cost efficiency. AI represents such a transformative technology that the opportunity exists to redesign and reimagine health altogether.

The coordination benefits emerge when AI systems can predict patient journeys across multiple touch points. This can work particularly well when hospitals and insurers share anonymised treatment pathway data. For example, AI algorithms can learn to identify patterns that suggest which patients might need specialised care, extended stays, or follow-up services.

Regulatory complexity multiplies when patient data crosses borders

Data standardisation and interoperability (the ability of computer systems or software to exchange and make use of information) remain the foundation. When hospitals and medical insurance providers use consistent coding systems and treatment protocols, AI can provide meaningful cost comparisons and care recommendations that are effective across borders and healthcare systems. 

Given your background in AI, what are the main technical and regulatory challenges in enabling seamless patient data exchange along provider-insurer networks – especially in cross-jurisdictional international private medical insurance (IPMI) cases?

The technical challenges centre on interoperability standards and data quality. European health systems often use different electronic health record formats, coding systems, and privacy frameworks than systems in Asia or the Americas. In the context of local and national healthcare systems, interoperability and data quality become increasingly important to the quality and efficiency of healthcare provision. This is also becoming more important in a global world with increased mobility and cross-border travel. Internationally agreed-upon standards become critical to achieving these objectives. Fortunately, taking the proper steps toward developing AI systems for better health will increase the holistic benefits of using AI in healthcare.

Regulatory complexity multiplies when patient data crosses borders. General Data Protection Regulation (GDPR) in Europe, the Personal Information Protection and Electronic Documents Act (PIPEDA) in Canada, and various national health information protection laws create a patchwork of compliance requirements. The challenge isn’t just understanding each jurisdiction’s rules but ensuring that data-sharing agreements can accommodate the most restrictive requirements while still enabling clinical care.

Authentication and patient consent management become particularly complex for mobile populations. A patient treated in Singapore who needs follow-up care in Germany requires systems that can verify identity, maintain consent preferences, and ensure clinical data remains accessible to authorised providers regardless of location.
 

How can insurers, hospitals, and tech vendors collaborate to ensure responsible, patient-centric AI deployment in IPMI?

Trust builds through transparency about AI decision-making processes. Successful AI implementation requires hospitals, insurers, and technology vendors to establish a human-centred design approach for explaining AI recommendations to patients and providers. This means moving beyond black-box algorithms toward explainable AI systems that can articulate why specific treatment or coverage decisions were recommended.

Data governance frameworks should include all stakeholders in determining how patient data is used for AI training and deployment. Patients need to have digital literacy to understand what data is being collected, how AI systems use this information, and what choices they have about participation.

Regular auditing of AI systems helps maintain trust. Collaborative audit processes in which insurers, hospitals, and technology vendors collaborate with patient organisations to evaluate AI performance, bias detection, and patient outcomes hold theoretical success. This shared accountability encourages responsible development and deployment practices.

What regulatory or contractual mechanisms can align B2B partnerships around outcome-based reimbursement for expatriate and mobile populations?

Contract structures need to define clear, measurable outcomes that work across different healthcare systems and populations. For expatriate care, this means establishing baseline health metrics that account for different disease prevalence patterns and healthcare access levels in patients’ home countries versus their current locations.

Regulatory frameworks should enable risk-sharing arrangements while protecting patient care quality.

Patients need to have digital literacy to understand what data is being collected, how AI systems use this information, and what choices they have about participation

However, in health systems, success depends in most cases on defining a reimbursement model, which in most countries is non-existent for these technologies. Everybody finds them fascinating and good to have, but, when push comes to shove, the question becomes: is it worth the investment? With so many competing priorities, these technologies sometimes fall through the cracks.

Data-sharing agreements become critical infrastructure for outcome-based models. Insurers need access to treatment effectiveness data, while hospitals need transparency about coverage criteria and reimbursement timelines. 

HealthAI’s collaboration with governments and international organisations contributes to ensuring that AI serves all populations equally in health. For example, HealthAI’s Global Regulatory Network (GRN) is a comprehensive international platform that brings together regulatory authorities from countries like the UK and Singapore to collaborate on AI health governance. The network operates alongside a Community of Practice with over 280 member organisations, focusing on capacity building, knowledge sharing, and ensuring responsible AI deployment in healthcare systems worldwide.

How can IPMI and hospital networks better ensure coverage continuity for travellers and staff during global health crises?

Coverage continuity requires flexible policy frameworks that can adapt quickly to travel restrictions and healthcare system disruptions. 

Hospital networks need redundancy planning that considers geopolitical risks alongside clinical capabilities. This means identifying alternative care locations for different types of treatments and establishing data-sharing protocols that can operate even when primary systems are disrupted.

Emergency communication systems should connect IPMI providers, hospital networks, and patients through multiple channels. Mobile apps, secure messaging platforms, and emergency hotlines need to function across different countries and network infrastructures.

HealthAI’s mission to ensure equitable access to AI-powered health innovations becomes critical during global health crises, particularly in low- and middle-income countries.

What international governance or accreditation can reassure IPMI customers on data protection, clinical standards, and AI ethics?

A certification framework like ISO standards could provide consistent benchmarks for data protection, clinical standards, and AI ethics across jurisdictions. This would give IPMI customers confidence that their data and care meet high standards regardless of where treatment occurs.

Third-party auditing organisations could provide independent verification of AI systems and data protection practices. 

These audits would follow internationally agreed standards but be conducted by organisations with deep understanding of local regulatory requirements.

How can hospital groups and IPMI providers use partnerships with regulators to expand access to advanced therapies while managing cost and complexity?

Regulatory harmonisation efforts, like those we’ve seen with the African Medicines Agency, create opportunities for IPMI providers to negotiate coverage for advanced therapies across multiple markets simultaneously. This reduces administrative complexity and can improve negotiating positions with pharmaceutical companies.

Remote diagnostic capabilities are becoming particularly valuable for expatriate populations, who may be far from specialised medical centres

Hospital groups can participate in international clinical trial networks, giving patients access to experimental treatments while generating evidence for broader coverage decisions. IPMI providers benefit by gaining early insights into treatment effectiveness and cost patterns.

Collaborative purchasing arrangements between hospital networks and IPMI providers can improve access to expensive therapies by pooling demand across different markets. This requires regulatory frameworks that permit such arrangements while maintaining appropriate oversight.

Looking ahead, which innovations – digital health, remote diagnostics, teleICU (remote monitoring of intensive care units), or AI triage – will most impact IPMI schemes and multinational hospitals?

Medical diagnosis represents a fundamental component of patient care, requiring precise determination of underlying health conditions. There is growing research that suggests primary care practices and telehealth platforms are incorporating AI-powered diagnostic solutions that help practitioners analyse patient symptoms through comparison with extensive clinical databases. This technological advancement facilitates faster diagnostic accuracy while expanding access to high-quality medical services, particularly benefiting populations in rural or medically underserved regions. Remote diagnostic capabilities are becoming particularly valuable for expatriate populations, who may be far from specialised medical centres. 

Digital health platforms that integrate across multiple healthcare systems could provide continuity for mobile populations. These platforms need to work with different electronic health record systems, maintain patient preferences across borders, and provide real-time access to treatment history and insurance coverage information.

The strategic impact comes from combining these innovations into comprehensive care ecosystems that serve mobile populations effectively while controlling costs and maintaining quality standards across different healthcare systems and regulatory environments.

HealthAI wants to see health technologies benefit every population worldwide. Our focus on driving equitable access to AI-powered health innovations ensures that these strategic developments don’t just serve affluent mobile populations but create inclusive health ecosystems that work for all. Through our governance and collaboration efforts, we’re helping ensure that AI innovations are deployed responsibly and accessibly across diverse global health environments.